chromosome 17 open reading frame 113Genealiases: []
Q-omics provides the consensus-scored C17orf113 profile across patient tissues and cancer cell-line models. C17orf113 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C17orf113 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, C17orf113 RNA expression shows 21,745 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where C17orf113 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C17orf113 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C17orf113 survival associations across molecular data types. C17orf113 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C17orf113 RNA expression–survival associations across cancer types. High C17orf113 expression shows unfavorable associations in MESO and OV, but favorable associations in KIRC, UVM, BRCA and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C17orf113 RNA expression.
This table summarizes C17orf113 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C17orf113. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C17orf113 shows lower tumor expression in THCA and BRCA and higher tumor expression in CHOL, COAD, LIHC and STAD. The THCA box plot shows higher C17orf113 RNA expression in normal versus tumor tissue (log2 FC = −1.238, t-test p < 0.001).
This table shows molecular features associated with C17orf113 in patient tissues and cancer cell lines. In patient samples, C17orf113 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, C17orf113 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
